Skip to content

Contact: Taran K. Deol, taran.deol@treatmentactiongroup.org

Rio de Janeiro, November 17, 2026 : Today’s tuberculosis (TB) vaccination landscape is limited to one century-old player — the Bacille Calmette-Guérin (BCG). The need for new TB vaccines is acute. With just one approved vaccine, whose protection wanes by adolescence, against the world’s deadliest infectious disease we are trying to plug a dam with a finger. However, we can change that. Investments in TB science over the last few years could soon begin to reap benefits. We are closer than ever to new TB vaccines, with several candidates in late-stage trials and results possible as early as 2028.

Translating potential clinical success into real world effectiveness requires preparing in advance. Communities must be ready to accept the vaccine, and healthcare providers must be on board to administer the vaccine. Policymakers need rollout plans for adolescents and adults, which will be challenging because most immunization programs are built around infants and children and will have to be bridged with TB programs. Researchers and developers should build community perspectives into trial design and communication, be transparent about pricing, licensing, and supply plans, and engage early with regulators and country decision makers.

To meet the need for a one-stop shop for new TB vaccines, TAG and partners have created the TB Vax Info Hub (Hub). A carefully curated resource platform, the Hub is designed to help stakeholders take the steps they need to prepare for new TB vaccines — educate communities, understand how vaccines and vaccine policy works, and strategize on engaging with policymakers. Based on your role in the TB vaccine response, resources can be sorted by audience including communities, policymakers, and researchers and developers. You can also browse by topic, by action, and by level, from basic to intermediate to advanced, to find what fits your needs and prior knowledge. 

New TB vaccines will be critical to achieving global TB elimination goals. The window to act is now. We must prepare for rollout even as clinical trials remain ongoing, so that health systems are ready to take them from labs to arms without delay. 

Explore the Hub, and help make sure no one is left behind.

Back To Top